1 of 1
Story summary
- CVS Health posted Q1 2026 earnings that beat expectations, lifted its full-year adjusted EPS and revenue outlook, and credited disciplined medical-cost controls and margin expansion in the Health Care Benefits segment.
- Analysts at JPMorgan Chase, Bernstein, SocGen Group and TD Cowen raised price targets, and shares climbed to $95.17 from $80.69 after the release.
- Analysts will watch Health100 adoption, biosimilar uptake and PBM regulatory changes for margin recovery in coming quarters.
